Exagamglogene autotemcel

Exagamglogene autotemcel (also known as Exa or Exa Auto) is a gene therapy product used in the treatment of cancer. It is a type of CAR-T cell therapy, which involves modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that targets a specific protein on cancer cells.

Mechanism of Action

Exagamglogene autotemcel works by targeting the CD19 protein, which is commonly found on the surface of B cells, including many types of B cell lymphoma and leukemia. The therapy involves collecting T cells from the patient, genetically modifying them in a laboratory to express a CAR that targets CD19, and then infusing the modified cells back into the patient. The CAR-T cells then seek out and destroy the cancer cells that express CD19.

Clinical Use

Exagamglogene autotemcel has been studied in clinical trials for the treatment of various types of B cell cancers, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma. It has shown promise in patients who have not responded to other treatments, including chemotherapy and stem cell transplant.

Side Effects

Like other CAR-T cell therapies, Exagamglogene autotemcel can cause serious side effects, including cytokine release syndrome (CRS) and neurotoxicity. CRS is a systemic inflammatory response that can cause fever, fatigue, and organ dysfunction, while neurotoxicity can cause confusion, seizures, and other neurological symptoms. Other potential side effects include infection, anemia, and thrombocytopenia.

Regulatory Status

As of the time of writing, Exagamglogene autotemcel is still in the experimental stages and has not been approved by regulatory authorities such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

See Also

• Gene therapy
• CAR-T cell therapy
• CD19
• Cytokine release syndrome
• Neurotoxicity

This article is a stub related to pharmacology. You can help WikiMD by expanding it!